Johnson & Johnson Tops Q3 2026 Estimates on EPS and Revenue, But Stock Slides Nearly 6%
By TrendSpider Editor
JNJ market update based on latest earnings data.
Johnson & Johnson Tops Q3 2026 Estimates on EPS and Revenue, But Stock Slides Nearly 6%
Johnson & Johnson reported Q3 2026 earnings per share of $2.59 before the market opened Tuesday, topping the consensus estimate of $2.53 by 2.37% and pushing revenue to $25.40 billion, a hair above the $25.39 billion estimate. Despite the dual beat, shares dropped 5.84% to $248.60, a reaction that underscores how much the market had already priced in strong results. The current price sits well off the 52-week high of $281.07, though it remains comfortably above the 52-week low of $184.66.Key Drivers of the JNJ Stock Move
- Main Catalyst: Johnson & Johnson delivered a Q3 2026 EPS of $2.59 against a $2.53 estimate, a 2.37% positive surprise, while revenue of $25.40 billion edged past forecasts by just 0.02%. The results were reported premarket on October 13, 2026.
- Bull Case: The company grew revenue 5.86% year over year, and EPS came in above expectations for the quarter. Both top- and bottom-line beats in the same report signal broad operational strength across JNJ's business segments.
- Bear Case: Despite the headline beats, earnings declined 7.5% on a year-over-year basis, which is a meaningful deterioration and likely the primary reason the stock is selling off sharply despite the consensus surprise. A revenue surprise of only 0.02% leaves virtually no cushion for investor disappointment.
JNJ Seasonality
Johnson & Johnson typically reports Q3 results in mid-October, and the stock has historically shown mixed reactions in the days immediately following the earnings release during this stretch of the year. With the broader healthcare sector navigating regulatory and pricing headwinds in the fall, seasonal tailwinds are not reliably strong enough to offset fundamental concerns like the current earnings compression.JNJ Relative Performance
JNJ's 5.84% single-session decline stands out as notably severe relative to typical large-cap healthcare stock moves on earnings days. Trading at $248.60, the stock is down significantly from its 52-week high of $281.07, representing a pullback of roughly 11.6% from that peak. The 52-week low of $184.66 provides longer-term structural support, but the current price action suggests near-term momentum has shifted to the downside, placing JNJ as an underperformer within the large-cap healthcare space following this morning's report.More on JNJ
- Johnson & Johnson Shares Slide 5.33% as Sellers Take Control in Tuesday Session
- Johnson & Johnson Sees Unusual Bullish Options Bet Worth $1.48M Targeting $290 by January 2028
- Johnson & Johnson Sees Unusual Options Activity as $845K Call Contract Hits Near 52-Week High
- Johnson & Johnson Stock Hovers Just Below Its 52-Week High as Bullish Momentum Builds
- Johnson & Johnson Surges to Within Striking Distance of Its 52-Week High as Shares Climb 1.40%
Latest Market News
- JP Morgan Lifts Apple Price Target to $360, Reaffirms Buy Near 52-Week High
- Meta Platforms Earns $1,000 Price Target From Truist as Four Analysts Reaffirm Buy Ratings
- JP Morgan Chase Misses Q3 2026 EPS and Revenue Estimates, But Shares Edge Higher in Early Trading
- Visa Stock Gets Baird Price Target Boost to $430 as Shares Push Past 52-Week High
- TD Cowen Raises CVX Price Target to $225 as Chevron Trades Near 52-Week High
- Merck Sees $1.17M in Unusual Call Activity Even as Shares Slide 2.45% Tuesday